In TCGA-BRCA and TCGA-PRAD patient datasets, both CCL22 and TNFSF10 expression were positively correlated with tumor infiltration of some immune cell types (Fig. 4A). This evidence concerns the gene CCL22 and prostate adenocarcinoma.